Brentuximab
Information about Brentuximab[edit source]
Brentuximab vedotin is a chimeric mouse-human monoclonal antibody to CD30 conjugated to a microtubule inhibitor which is used in the therapy of Hodgkin lymphoma and anaplastic large cell lymphoma.
Liver safety of Brentuximab[edit source]
Brentuximab vedotin has been linked to mild and transient serum enzyme elevations during therapy, but has not been implicated in cases of clinically apparent acute liver injury.
Mechanism of action of Brentuximab[edit source]
Brentuximab (bren tux’ i mab) vedotin (ve doe’ tin) is a chimeric mouse-human monoclonal IgG1 antibody to the human CD30 cell surface marker, which is also known as tumor necrosis factor receptor superfamily, member 8 and which is expressed on malignant cells particularly in Hodgkin lymphoma. The monoclonal antibody is conjugated to a microtubule inhibitor, monomethyl auristatin E (MMAE, also known as vedotin). When brentuximab vedotin binds to CD30, it is inteRNAlized and the MMAE is released by the action of lysosomal enzymes on the linker molecule that joins brentuximab to vedotin. This monoclonal antibody conjugate has been shown to be effective in inducing remissions in refractory Hodgkin lymphoma and anaplastic large cell lymphoma, and was approved for these indications in the United States in 2011.
Dosage and administration for Brentuximab[edit source]
Brentuximab is available as a lyophilized powder (50 mg) and in liquid solution in (50 mg in 25 mL) in single dose vials under the brand name Adcetris. The recommended regimen is 1.8 mg/kg by intravenous infusion every three weeks until disease progression or unacceptable toxicity.
Side effects of Brentuximab[edit source]
Common side effects include infusion reactions, peripheral neuropathy, fatigue, nausea, diarrhea, headache, skin rash, chills, fever, leucopenia and thrombocytopenia. Less common, but serious side effects include infections, severe cutaneous reactions including Stevens Johnson syndrome, tumor lysis syndrome, peripheral neuropathy, pulmonary toxicity and progressive multifocal leukoencephalopathy. Alphabetic list of antineoplastic agents - 0-9 - A1 - A2 - A3 - A4 - A5 -A6 - B - C - D - E - F - G - H - I - JK - L - M - NO - PQ - R - S - T - UVW - XYZ
| Brentuximab Resources | |
|---|---|
|
 |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
